Revenue from operations grew 19.1% to ₹797.7 crore from ₹669.8 crore a year ago, supported by improved operating performance. Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 28.7% year-on-year to ₹247.5 crore from ₹192.3 crore, while EBITDA margin expanded to 31% from 28.7% in the year-ago period.
Profit before tax rose to ₹228.7 crore from ₹181.1 crore, while total tax expense increased to ₹58.2 crore from ₹47.1 crore a year earlier.
The board declared an interim dividend of ₹5 per equity share, or 50% of the face value of ₹10 each, for FY27. The record date for determining eligible shareholders has been fixed as July 30, with the dividend to be paid within 30 days of its declaration.
Separately, the company said its wholly owned subsidiary, Dr Lal PathLabs FZCO, approved the acquisition of an 80% stake in Ghana-based Sunshine Healthcare Ltd for up to GHS 45.6 million (around ₹38 crore) in the first tranche, strengthening its presence in West Africa.
Another wholly owned subsidiary, Dr Lal Ventures Pvt Ltd, approved the acquisition of a 30% stake in Neuome Technologies Pvt Ltd for up to ₹3.5 crore to gain access to sample preservation, pre-analytical technologies and biobanking solutions.
Shares of Dr Lal PathLabs were trading 1.17% higher at ₹1,706.80 following the Q1 results announcement on Friday. The stock has gained about 13% so far this year and more than 10% over the last 12 months.
